BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18232729)

  • 1. Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.
    Jain RK; Lahdenranta J; Fukumura D
    PLoS Med; 2008 Jan; 5(1):e24. PubMed ID: 18232729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
    Pietras K; Pahler J; Bergers G; Hanahan D
    PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDGF receptors as targets in tumor treatment.
    Ostman A; Heldin CH
    Adv Cancer Res; 2007; 97():247-74. PubMed ID: 17419949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
    Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
    Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
    J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
    Sumida T; Kitadai Y; Shinagawa K; Tanaka M; Kodama M; Ohnishi M; Ohara E; Tanaka S; Yasui W; Chayama K
    Int J Cancer; 2011 May; 128(9):2050-62. PubMed ID: 21387285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.
    McCarty MF; Somcio RJ; Stoeltzing O; Wey J; Fan F; Liu W; Bucana C; Ellis LM
    J Clin Invest; 2007 Aug; 117(8):2114-22. PubMed ID: 17641778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.
    Shimizu A; O'Brien KP; Sjöblom T; Pietras K; Buchdunger E; Collins VP; Heldin CH; Dumanski JP; Ostman A
    Cancer Res; 1999 Aug; 59(15):3719-23. PubMed ID: 10446987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers.
    Murata T; Mizushima H; Chinen I; Moribe H; Yagi S; Hoffman RM; Kimura T; Yoshino K; Ueda Y; Enomoto T; Mekada E
    Cancer Res; 2011 Nov; 71(21):6633-42. PubMed ID: 22009535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay.
    Yener U; Avsar T; Akgün E; Şeker A; Bayri Y; Kılıç T
    J Neurosurg; 2012 Oct; 117(4):697-704. PubMed ID: 22900848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of GIST.
    Blanke C
    Clin Adv Hematol Oncol; 2004 May; 2(5):280, 283. PubMed ID: 17682286
    [No Abstract]   [Full Text] [Related]  

  • 13. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
    Taïeb A; Constans J; Mahon FX
    Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.
    Falcon BL; Pietras K; Chou J; Chen D; Sennino B; Hanahan D; McDonald DM
    Am J Pathol; 2011 Jun; 178(6):2920-30. PubMed ID: 21641409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective role of imatinib in atherosclerosis.
    Kadowaki T; Kubota N
    Arterioscler Thromb Vasc Biol; 2004 May; 24(5):801-3. PubMed ID: 15132971
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
    Joensuu H; De Braud F; Coco P; De Pas T; Putzu C; Spreafico C; Bono P; Bosselli S; Jalava T; Laurent D; Casali PG
    Ann Oncol; 2008 Jan; 19(1):173-7. PubMed ID: 17698976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
    Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
    Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.
    Rosenberg A; Mathew P
    Expert Opin Investig Drugs; 2013 Jun; 22(6):787-94. PubMed ID: 23540855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
    Chhina MK; Nargues W; Grant GM; Nathan SD
    Future Cardiol; 2010 Jan; 6(1):19-35. PubMed ID: 20014985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing tumor uptake of anticancer drugs with imatinib.
    Pietras K
    Semin Oncol; 2004 Apr; 31(2 Suppl 6):18-23. PubMed ID: 15176000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.